Drug
Ruzinurad clinical trials
Also written SHR4640.
- studies test it
- 19
- open now
- 1
- in phase 3
- 2
- first study started
- 2015
Keep track of what changes. Save the ruzinurad studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 3
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- Gout
- 4
Who runs them
Industry 19 · Other 0
Jiangsu HengRui Medicine Co., Ltd. (17) · Atridia Pty Ltd. (2)
Often tested with
Tested in the same studies.
Febuxostat (2) · Repaglinide (1) · Midazolam (1) · Furosemide (1) · Colchicine (1)
Studies
Open first, then newest update. How each study uses ruzinurad is read from its arms, and is right about nine times in ten.
Testing it · 19
- The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and HyperuricemiaRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07362355Written as SHR4640 ;Febuxostat
- A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With GoutCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT04956432Written as SHR4640
- Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05954169Written as SHR4640
- PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT IntervalCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06196580Written as repaglinide; midazolam; SHR4640
- Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06168929Written as SHR4640
- Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and HyperuricemiaStatus unknownPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT05513976Written as SHR4640 tablet
- Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic ImpairmentStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04305392Written as SHR4640
- Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)CompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04850638Written as SHR4640 tablets and furosemide tablets
- A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With GoutCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT04052932Written as SHR4640 dose1
- Study on the Food Effects of Oral SHR4640 Tablets in Healthy VolunteersStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04620408Written as SHR4640
- Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy VolunteersStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04586803Written as SHR4640
- Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.CompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04260373Written as [14C]SHR4640
- The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With HyperuricemiaStatus unknownPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT04157959Written as SHR4640 dose1
- The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With GoutCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT03131583Written as SHR4640
- Dose-finding and Safety Study of SHR4640 in Subjects With HyperuricemiaCompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT03185793Written as SHR4640
- A Single Dose Study of SHR4640 in Healthy Male VolunteersCompletedPhase 1Atridia Pty Ltd.NCT03015948Written as SHR4640
- Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid LevelCompletedPhase 1Atridia Pty Ltd.NCT03211403Written as SHR4640
- Multiple Dose Study of SHR4640 in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT02890966Written as SHR4640
- Single Dose Study of SHR4640 in Healthy SubjectsCompletedPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT02815839Written as SHR4640
Codes
What other systems call ruzinurad · ClinicalTrials.gg INT001769
- MeSH (NLM) C000720748ruzinuradOne source NLM
- UNII (FDA) UP8J9CA76IRUZINURADConfirmed FDA, NLM, Wikidata
- Wikidata Q123466253ruzinuradConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C184933RuzinuradOne source FDA
- DrugBank DB19209One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720748 | ruzinurad | One source NLM |
| UNII (FDA) | UP8J9CA76I | RUZINURAD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123466253 | ruzinurad | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C184933 | Ruzinurad | One source FDA |
| DrugBank | DB19209 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.